Payment overview · 2025
General Payments
$273.61
4 reported records · 3 companies
Healthcare provider profile · identity verified
Suresh P Thomas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BECKLEY, WV · NPI 1700967122
Verified facts
What the public records show
CMS Open Payments records show Suresh P Thomas, MD received $273.61 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $140.97 | 51.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $81.59 | 29.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.05 | 18.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.61 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.49 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $81.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.05 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
198 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 821 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 549 | 127 |
| Lisinopril | Lisinopril | 473 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 452 | 119 |
| Metformin Hcl | Metformin Hcl | 414 | 87 |
| Furosemide | Furosemide | 386 | 80 |
| Omeprazole | Omeprazole | 384 | 102 |
| Simvastatin | Simvastatin | 341 | 77 |
| Eliquis | Apixaban | 340 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 86 |
| Losartan Potassium | Losartan Potassium | 299 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 288 | 72 |
| Potassium Chloride | Potassium Chloride | 277 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 266 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 63 |
| Sertraline Hcl | Sertraline Hcl | 232 | 34 |
| Gabapentin | Gabapentin | 219 | 39 |
| Famotidine | Famotidine | 217 | 41 |
| Ozempic | Semaglutide | 198 | 28 |
| Montelukast Sodium | Montelukast Sodium | 190 | 31 |
| Carvedilol | Carvedilol | 184 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 47 |
| Allopurinol | Allopurinol | 170 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 144 | 27 |
| Lorazepam | Lorazepam | 143 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 23 |
| Alprazolam | Alprazolam | 141 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 39 |
| Tramadol Hcl | Tramadol Hcl | 128 | 26 |
| Xarelto | Rivaroxaban | 123 | 14 |
| Spironolactone | Spironolactone | 122 | 25 |
| Synthroid | Levothyroxine Sodium | 118 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 30 |
| Glipizide | Glipizide | 113 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 13 |
| Valsartan | Valsartan | 103 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 38 |
| Atenolol | Atenolol | 96 | 25 |
| Buspirone Hcl | Buspirone Hcl | 95 | 19 |
| Donepezil Hcl | Donepezil Hcl | 95 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | suppressed |
| Finasteride | Finasteride | 87 | 20 |
| Levetiracetam | Levetiracetam | 87 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 24 |
| Alendronate Sodium | Alendronate Sodium | 83 | 19 |
| Pregabalin | Pregabalin | 83 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 22 |
| Meloxicam | Meloxicam | 75 | 17 |
| Metformin Hcl Er | Metformin Hcl | 75 | 20 |
| Warfarin Sodium | Warfarin Sodium | 75 | 15 |
| Glipizide Er | Glipizide | 73 | 17 |
| Risperidone | Risperidone | 73 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 73 | 15 |
| Trulicity | Dulaglutide | 71 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 17 |
| Entresto | Sacubitril/Valsartan | 66 | 13 |
| Farxiga | Dapagliflozin Propanediol | 66 | suppressed |
| Januvia | Sitagliptin Phosphate | 63 | 14 |
| Mounjaro | Tirzepatide | 63 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 54 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 54 | suppressed |
| Cephalexin | Cephalexin | 51 | 34 |
| Mirtazapine | Mirtazapine | 51 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | 19 |
| Clonidine Hcl | Clonidine Hcl | 48 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 16 |
| Glimepiride | Glimepiride | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | 12 |
| Ezetimibe | Ezetimibe | 39 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 16 |
| Letrozole | Letrozole | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | 11 |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Prednisone | Prednisone | 31 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 28 |
| Ketoconazole | Ketoconazole | 30 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Nystatin | Nystatin | 28 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 25 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 26 | suppressed |
| Colchicine | Colchicine | 25 | 11 |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 14 |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Linzess | Linaclotide | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Theo-24 | Theophylline Anhydrous | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.61 · 4 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, FREESTYLE LIBRE 3, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error